Quince Therapeutics (QNCX) Enterprise Value (2019 - 2026)

Quince Therapeutics has reported Enterprise Value for 8 years, with the latest figure at $139.4 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 560.2% year-over-year to $139.4 million in Q2 2026; TTM through Jun 2026 was $139.4 million, a 560.2% increase from a year earlier, with the FY2025 full-year figure at -$8.4 million, up 77.04% from the prior year.
• Enterprise Value was $139.4 million for Q2 2026 at Quince Therapeutics, up from -$17.7 million in the prior quarter.
• The five-year high for Enterprise Value was $139.4 million in Q2 2026, with the low at -$109.9 million in Q1 2024.
• Average Enterprise Value over 5 years is -$49.9 million, with a median of -$65.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value sank 509.18% in 2022, then surged 560.2% in 2026.
• Over 5 years, Enterprise Value stood at -$89.0 million in 2022, then advanced by 18.23% to -$72.8 million in 2023, then jumped by 49.63% to -$36.7 million in 2024, then jumped by 77.04% to -$8.4 million in 2025, then surged by 1755.58% to $139.4 million in 2026.
• The last three Enterprise Value figures came in at $139.4 million (Q2 2026), -$17.7 million (Q1 2026), and -$8.4 million (Q4 2025), per Business Quant data.